Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan after kidney transplantation to reduce fibrosis and preserve graft function
ISRCTN15884223Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of losartan in kidney allograft rejection and renal allograft fibrosis (IF/TA) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Graft function by estimated glomerular filtration rate and Fibrosis biomarkers. Started Nov 2013; status: completed.
02
Drugs
losartan
03
Conditions
kidney allograft rejectionrenal allograft fibrosis (IF/TA)
Beyond the preview
Go deeper on ISRCTN15884223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15884223.